Chemoprevention with chlorophyllin in individuals exposed to dietary aflatoxin

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 523-524, Issue , 2003, Pages 209-216

  Egner, Patricia A ^a   Muñoz, Alvaro ^a   Kensler, Thomas W ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aflatoxins; Chemoprevention; Chlorophyllin

Indexed keywords

AFLATOXIN; AFLATOXIN 8,9 EPOXIDE; AFLATOXIN B1; AFLATOXIN N 7 GUANINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHLOROPHYLL; EPOXIDE; FOOD DYE; GUANINE DERIVATIVE; UNCLASSIFIED DRUG; WATER;

CANCER RISK; CARCINOGENIC ACTIVITY; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DNA ADDUCT; DRUG BIOAVAILABILITY; EXPERIMENTAL MODEL; EXPOSURE; HIGH RISK POPULATION; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; METABOLITE; PRIORITY JOURNAL; PROSPECTIVE STUDY; URINARY EXCRETION;

HEPATITIS B VIRUS;

EID: 0037293066     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(02)00337-8     Document Type: Conference Paper

References (38)

1. W.F.J. Busby, G.N. Wogan, Aflatoxins, in: C.B. Searle (Ed.), Chemical Carcinogens, Second ed., American Chemical Society, Washington, DC, 1984, pp. 945-1136.
2. Aflatoxins, IARC Monogr. Evaluation Carcinogenic Risks Hum. 56 (1993) 245-395.
3. National Cancer Office of the Ministry of Public Health, PRC, Studies on Mortality Rates of Cancer in China, Peoples Publishing House, 1980.
4. Ross R.K., Yuan J.-M., Mu M.C., Wogan G.N., Qian G.-S., Tu J.-T., Groopman J.D., Gao Y.-T., Henderson B.E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 339:1992;943-946.
5. Qian G.-S., Ross R.K., Mu M.C., Yuan J.-M., Gao Y.-T., Henderson B.E., Wogan G.N., Groopman J.D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer in Shanghai, Peoples Republic of China. Cancer Epidemiol. Biomarkers Prev. 5:1996;253-261.
6. Wang L.-Y., Hatch M., Chen C.-J., Levin B., You S.-L., Lu S.-N., Wu M.-H., Wu W.-P., Wang L.-W., Wang Q., Huang G.-T., Yang P.-M., Lee H.-S., Santella R.M. Aflatoxin exposure and the risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer. 67:1996;620-625.
7. Chang M.-H., Chen C.-J., Lai M.-S., Hsu H.-M., Wu T.C., Kong M.S., Liang D.C., Shau W.-Y., Chen D.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. New Engl. J. Med. 336:1997;1855-1859.
8. Hayatsu H., Arimoto S., Negishi T. Dietary inhibitors of mutagenesis and carcinogenesis. Mutat. Res. 202:1988;429-446.
9. Dragsted L.O., Strube M., Larsen J.C. Cancer-protective factors in fruits and vegetables: biochemical and biological background. Pharmacol. Toxicol. 72:1993;116-135.
10. Kephart J.C. Chlorophyll derivatives - their chemistry, commercial preparation and uses. Econ. Bot. 9:1955;3-38.
11. M.G. Ferruzzi, D.A. Garrett, M.L. Failla, S.J. Schwartz, Chlorophyll degradation products are micellarized from spinach puree by an in vitro digestion process, in: Proceedings of the IFT Annual Meeting, Abstract #65E-2, 2001.
12. Young R.W., Bergei J.S. Use of chlorophyllin in the care of geriatric patients. J. Am. Geriat. Soc. 24:1980;46-47.
13. Waters M.D., Stack H.F., Jackson H.E., Brockman D., DeFlora S. Activity profiles of antimutagens: in vitro and in vivo data. Mutat. Res. 350:1996;109-129.
14. Negishi T., Rai H., Hayatsu H. Antigenotoxic activity of natural chlorophylls. Mutat. Res. 376:1997;55-68.
15. 1. A review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Mutat. Res. 399:1998;245-253.
16. Negishi T., Arimoto S., Nishizaki C., Hayatsu H. Inhibitory effect of chlorophyll on the genotoxicity of 3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2). Carcinogenesis. 10:1989;145-149.
17. 1. Complex formation with the carcinogen. Chem. Res. Toxicol. 8:1995;506-514.
18. Sato M., Fujimoto I., Sakai T., Aimoto T., Kimura R., Murata T. Effect of sodium copper chlorophyllin on lipid peroxidation IX. On the antioxidative components in commercial preparations of sodium copper chlorophyllin. Chem. Pharm. Bull. 34:1986;2428-2434.
19. Yun C., Hye G.J., Jhoun J.W., Guengerich F.P. Non-specific inhibition of cytochrome P450 activities by chlorophyllin in human and rat liver microsomes. Carcinogenesis. 16:1995;1437-1440.
20. Imai K., Aimoto T., Sato M., Watanabe K., Kimura R., Murata T. Effect of sodium metallochlorophyllins on the activity and components of the drug microsomal metabolizing enzyme system in the rat liver. Chem. Pharm. Bull. 34:1986;4287-4293.
21. 1 hepatocarcinogenesis in rainbow trout. Cancer Res. 55:1995;57-62.
22. Kensler T.W., Groopman J.D., Roebuck B.D. Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man. Mutat. Res. 402:1998;165-172.
23. Jacobson L.P., Zhang B.-C., Zhu Y.-R., Wang J.-B., Wu Y., Zhang Q.-N., Yu Y.-L., Qian G.-S., Kuang S.-Y., Li Y.-F., Fang X., Zarba A., Chen B., Enger C.L., Davidson N.E., Gordon G.B., Gorman M.B., Prochaska H.J., Egner P.A., Groopman J.D., Muñoz A., Helzlsouer K.J., Kensler T.W. Oltipraz chemoprevention trial in Qidong, Peoples Republic of China: study design and clinical outcomes. Cancer Epidemiol. Biomarkers Prev. 6:1996;257-265.
24. 4 ethyl ester in sera of individuals participating in the chlorophyllin chemoprevention trial. Chem. Res. Toxicol. 13:2000;900-906.
25. Egner P.A., Wang J.-B., Zhu Y.-R., Zhang B.-C., Wu Y., Zhang Q.-N., Qian G.-S., Kuang S.-Y., Gange S.J., Jacobson L.P., Helzlsouer K.J., Bailey G.S., Groopman J.D., Kensler T.W. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc. Natl. Acad. Sci. 98:2001;14601-14606.
26. Kensler T.W., He X., Otieno M., Egner P.A., Jacobson L.P., Chen B., Wang J.S., Wu Y., Zhang Q.-N., Qian G.-S., Kuang S.-Y., Fang A., Li Y.-F., Yu L.-Y., Prochaska H.J., Davidson N.E., Gordon G.B., Gorman M.B., Zarba A., Enger C., Muñoz A., Helzlsouer K.J., Groopman J.D. Oltipraz chemoprevention trial in Qidong, Peoples Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev. 7:1998;127-134.
27. Walton M., Egner P.A., Scholl P.F., Walker J., Kensler T.W., Groopman J.D. Liquid chromatography electrospray-mass spectrometry of urinary aflatoxin biomarkers: characterization and application to dosimetry and chemoprevention in rats. Chem. Res. Toxicol. 14:2001;919-926.
28. 1 in vitro. Proc. Natl. Acad. Sci. 74:1977;1870-1874.
29. 1-treated rats. Cancer Res. 41:1981;650-654.
30. Groopman J.D., Zhu J.-Q., Donahue P.R., Pikul A., Zhang L.-S., Chen J.-S., Wogan G.N. Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, Peoples Republic of China. Cancer Res. 52:1992;45-52.
31. Greenblatt M.S., Bennett W.P., Holstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
32. 7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res. 46:1986;3924-3931.
33. 7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1.2-dithiole-3-thione in rats. Carcinogenesis. 13:1992;101-106.
34. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res. 51:1991;5501-5506.
35. Kensler T.W., Groopman J.D., Sutter T.R., Curphey T.J., Roebuck B.D. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem. Res. Toxicol. 12:1999;113-126.
36. Kensler T.W., Gange S.J., Egner P.A., Dolan P.M., Muñoz A., Groopman J.D., Rogers A.E., Roebuck B.D. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 6:1997;603-610.
37. Koulibaly M., Kabba I.S., Cisse A., Diallo S.B., Diallo M.B., Keita N., Camara N.D., Diallo M.S., Sylla B.S., Parkin D.M. Cancer incidence in Conakry, Guinea: first results from the cancer registry 1992-1995. Int. J. Cancer. 70:1997;39-45.
38. Loeb L.A. A mutator phenotype in cancer. Cancer Res. 61:2001;3230-3239.